Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer

Kim Y C Fung; Ilka Priebe; Leanne Purins; Bruce Tabor; Gemma V Brierley; Trevor Lockett; Edouard Nice; Peter Gibbs; Jeannie Tie; Paul McMurrick; James Moore; Andrew Ruszkiewicz; Antony Burgess; Leah J Cosgrove

doi:10.3233/CBM-130335

Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer

Kim Y C Fung, Ilka Priebe, Leanne Purins, Bruce Tabor, Gemma V Brierley, Trevor Lockett, Edouard Nice, Peter Gibbs, Jeannie Tie, Paul McMurrick, James Moore, Andrew Ruszkiewicz, Antony Burgess, Leah J Cosgrove

Research output: Contribution to journal › Article › Research › peer-review

15 Citations (Scopus)

Abstract

BACKGROUND: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. METHODS: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). RESULTS: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort. Receiver operating characteristic analysis was performed to determine its performance as a diagnostic marker. The area under the curve was found to be 0.641 (95% confidence interval 0.576-0.706). Furthermore, the sensitivity of lipocalin 2 was found to be 24% at 90% specificity. CONCLUSIONS: Our study indicates that lipocalin 2 is not a suitable serum biomarker for the diagnosis of CRC.

Original language	English
Pages (from-to)	75-79
Number of pages	5
Journal	Cancer Biomarkers
Volume	13
Issue number	2
DOIs	https://doi.org/10.3233/CBM-130335
Publication status	Published - 2013
Externally published	Yes

Keywords

biomarker
blood
Colorectal cancer
diagnosis
lipocalin 2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3233/CBM-130335

Cite this

@article{f6382e69ff3546b29e0cd01d65fdf0b6,

title = "Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer",

abstract = "BACKGROUND: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. METHODS: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). RESULTS: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort. Receiver operating characteristic analysis was performed to determine its performance as a diagnostic marker. The area under the curve was found to be 0.641 (95% confidence interval 0.576-0.706). Furthermore, the sensitivity of lipocalin 2 was found to be 24% at 90% specificity. CONCLUSIONS: Our study indicates that lipocalin 2 is not a suitable serum biomarker for the diagnosis of CRC.",

keywords = "biomarker, blood, Colorectal cancer, diagnosis, lipocalin 2",

author = "Fung, {Kim Y C} and Ilka Priebe and Leanne Purins and Bruce Tabor and Brierley, {Gemma V} and Trevor Lockett and Edouard Nice and Peter Gibbs and Jeannie Tie and Paul McMurrick and James Moore and Andrew Ruszkiewicz and Antony Burgess and Cosgrove, {Leah J}",

year = "2013",

doi = "10.3233/CBM-130335",

language = "English",

volume = "13",

pages = "75--79",

journal = "Cancer Biomarkers",

issn = "1574-0153",

publisher = "IOS Press",

number = "2",

}

TY - JOUR

T1 - Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer

AU - Fung, Kim Y C

AU - Priebe, Ilka

AU - Purins, Leanne

AU - Tabor, Bruce

AU - Brierley, Gemma V

AU - Lockett, Trevor

AU - Nice, Edouard

AU - Gibbs, Peter

AU - Tie, Jeannie

AU - McMurrick, Paul

AU - Moore, James

AU - Ruszkiewicz, Andrew

AU - Burgess, Antony

AU - Cosgrove, Leah J

PY - 2013

Y1 - 2013

N2 - BACKGROUND: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. METHODS: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). RESULTS: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort. Receiver operating characteristic analysis was performed to determine its performance as a diagnostic marker. The area under the curve was found to be 0.641 (95% confidence interval 0.576-0.706). Furthermore, the sensitivity of lipocalin 2 was found to be 24% at 90% specificity. CONCLUSIONS: Our study indicates that lipocalin 2 is not a suitable serum biomarker for the diagnosis of CRC.

AB - BACKGROUND: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. METHODS: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). RESULTS: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort. Receiver operating characteristic analysis was performed to determine its performance as a diagnostic marker. The area under the curve was found to be 0.641 (95% confidence interval 0.576-0.706). Furthermore, the sensitivity of lipocalin 2 was found to be 24% at 90% specificity. CONCLUSIONS: Our study indicates that lipocalin 2 is not a suitable serum biomarker for the diagnosis of CRC.

KW - biomarker

KW - blood

KW - Colorectal cancer

KW - diagnosis

KW - lipocalin 2

UR - http://www.scopus.com/inward/record.url?scp=84880566580&partnerID=8YFLogxK

U2 - 10.3233/CBM-130335

DO - 10.3233/CBM-130335

M3 - Article

C2 - 23838135

AN - SCOPUS:84880566580

SN - 1574-0153

VL - 13

SP - 75

EP - 79

JO - Cancer Biomarkers

JF - Cancer Biomarkers

IS - 2

ER -

Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this